Detalhe da pesquisa
1.
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Haematologica
; 108(8): 2091-2100, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36632738
2.
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
Br J Haematol
; 196(3): 559-565, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34636033
3.
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study.
Haematologica
; 107(10): 2356-2364, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35385922
4.
Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study.
Chemotherapy
; 67(2): 91-95, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-34872098
5.
Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
Expert Opin Emerg Drugs
; 25(1): 25-35, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31996046
6.
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group.
Am J Hematol
; 95(6): 604-611, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32096887
7.
Sustained Complete Remission with Incomplete Hematologic Recovery (CRi) in a Patient with Relapsed AML and Concurrent BCR-ABL1 and CBFB Rearrangement Treated with a Combination of Venetoclax and 5-Azacytidine.
Chemotherapy
; 65(1-2): 51-53, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32570264
8.
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.
Haematologica
; 104(8): 1589-1596, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30819917
9.
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.
Cancer
; 124(10): 2228-2237, 2018 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29499087
10.
Sustained Erythroid Response in a Patient with Myelofibrosis Receiving Concomitant Treatment with Ruxolitinib and Deferasirox.
Chemotherapy
; 63(2): 107-110, 2018 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29694973
11.
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia.
Haematologica
; 102(9): 1530-1536, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28572163
12.
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model.
Am J Hematol
; 97(5): E176-E180, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35170793
13.
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
Am J Hematol
; 92(8): 797-805, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28466557
14.
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.
Haematologica
; 101(10): 1200-1207, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27470600
15.
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report.
Hematol Oncol
; 39(4): 570-574, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34258787
16.
Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson Cancer Center model.
Eur J Haematol
; 96(1): 72-7, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25819739
17.
Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study.
Eur J Haematol
; 96(1): 36-45, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25753656
18.
The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients.
Am J Hematol
; 91(11): 1090-1095, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27465919
19.
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia.
Am J Hematol
; 91(6): 617-22, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26971721
20.
Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis.
Blood
; 131(3): 365-368, 2018 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-29084773